Clinigen Group plc, of Staffordshire, U.K., said its Idis Global Access division signed an exclusive supply agreement with Galen Ltd., a privately owned pharmaceutical sales and marketing company. Under terms of the supply agreement, Idis will provide Galen's chemotherapy drug Daunoxome (daunorubicin citrate - 2 mg/ml-concentrate for solution for Infusion) to health care professionals on an on-demand basis in 20 European countries, Australia, New Zealand and Hong Kong, where it is unlicensed at the point of care. Galen retained the rights to supply Daunoxome in the U.K. and selected countries outside Europe. It has Medicines and Healthcare products Regulatory Agency approval to treat AIDS-related Kaposi's sarcoma.